Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan Combination in Advanced Solid Tumors
NCT04976634Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of belzutifan in hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and 3 more (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity at 21 days, Adverse Events at 67 months and 2 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04976634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976634.